Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Tirzepatide and SGLT2 drugs in HFpEF
A 2026 review sets tirzepatide against the SGLT2 inhibitors in obesity-related HFpEF. The mechanisms look complementary. No trial has tested them together.
MASH screening in type 2 diabetes
A new model finds staged, non-invasive MASH screening cost-effective for adults with type 2 diabetes across six countries.
Melanotan 1: why the tan comes out patchy
Melanotan 1 triggers melanin in all skin, not just sun-exposed surfaces, which explains tiger-stripe pigmentation in people with loose or aged skin.
A semaglutide case report on dysautonomia
A 2026 case report described symptom improvement after semaglutide in one patient with dysautonomia. It does not establish a treatment.
Semaglutide and endothelial markers
A post hoc randomized-trial analysis found mixed endothelial marker results after 32 weeks of semaglutide in type 2 diabetes.
Does tirzepatide cut carpal tunnel risk?
A 2026 cohort study links tirzepatide to fewer carpal tunnel diagnoses than other weight drugs. That is an association, not a treatment effect.
Tirzepatide: 6-month US persistence data
68% of US adults who started tirzepatide stayed on it at six months. A claims study of 22,512 initiators shows real-world persistence outside the trial setting.
Why GLP-1 prescriptions go unfilled
About 40% of GLP-1 orders are never dispensed. Here is what the fill-rate evidence on semaglutide and tirzepatide shows, and what it cannot show.
The evolution of obesity medications
A 2026 review traces obesity drugs from withdrawn stimulants to semaglutide and tirzepatide, and sets out what the newer agents still cannot do.
Finding at-risk MASH without a liver biopsy
With semaglutide approved for MASH, finding the right patients is the bottleneck, and a new study says a liver stiffness scan can do it without a biopsy.
Peptide supplements in sports medicine
A 2026 UCLA scoping review checked six peptides sold for recovery and performance, including CJC-1295 and BPC-157, against the actual human trial evidence.
Semaglutide, Alzheimer's and mouse data
A September 2026 mouse study reports semaglutide reduced a form of hippocampal neuron death, months after the human evoke trials missed their endpoint.